Merck KGaA Stock Timeline

2021 — COVID aftermath, life‑science strength

Recovery from COVID‑19 shock enabled continued strong demand in Life Science as research and biopharma activity normalised after 2020. Early‑stage M&A activity and bolt‑on deals in life‑science businesses accelerated during this period [1][3].

Perception shifted from pandemic‑era revenue distortion toward a durable Life Science growth story supported by Sigma‑Aldrich integration and recurring consumables demand. Investors began viewing Merck as a diversified science & technology compounder rather than a pure cyclical chemical player.

The stock entered a post‑pandemic rally into an uptrend with higher highs as markets re‑rated the recurring revenues of Life Science.

2022 — Semiconductor and Electronics push with targeted tech buys

Strategic investment in Electronics accelerated, particularly in semiconductor materials. Acquisitions such as Mecaro Co. Ltd. and other targeted life‑science and electronics bolt‑ons were announced or closed to strengthen semiconductor and lab offerings [1].

Investor view broadened considerably. Merck was increasingly seen as a diversified technology platform with secular exposure to semiconductor demand and resilient Life Science cash flows. The growth story gained credibility while Electronics cyclicality remained a watchpoint.

The stock extended its uptrend with intermittent profit‑taking during macro volatility driven by inflation and rate‑hike periods, forming a higher base.

2023 — Execution, selective tuck‑ins and focus on specialty growth

Multiple tuck‑in deals and continued expansion of Life Science and Healthcare franchises proceeded through the year. Annual reporting highlighted organic growth drivers and integration progress for prior large acquisitions [11].

Market perception treated Merck as executing on a multi‑year transformation from chemicals conglomerate toward high‑margin life‑science and specialty electronics exposure. Investor confidence improved though valuation was considered premium for quality given the cyclically exposed Electronics business.

The stock traded in a range with upward bias as investors balanced growth credentials against macro risk, with rotational volatility around quarterly results.

2024 — Larger strategic deals and accelerating Electronics momentum

Material deals including Mirus Bio and Unity‑SC were announced and closed to bolster Life Science and Electronics segments. Management emphasised innovation and vertical expansion in semiconductor materials and biologics production [1].

Perception shifted to a more pronounced growth bias as investors rewarded strategic acquisitions that enhanced addressable markets in bioprocessing and semiconductor materials. Some skepticism persisted regarding near‑term dilution and integration risk.

Breakout rallies on positive deal and news flow were punctuated by short drawdowns on profit‑taking and macro headlines. The trend resumed higher into year‑end 2024.

2025 — Transformational SpringWorks acquisition and resilient results against FX headwinds

A major healthcare acquisition of SpringWorks Therapeutics (~$3.4bn) was announced and closed alongside other 2025 deals. Full‑year 2025 net sales reached €21.1bn and EBITDA pre €6.1bn, with organic growth of approximately 3.1% offset by negative FX impacts on reported figures [4][1].

Investors saw Merck doubling down on higher‑value therapeutics and life‑science capabilities. Strong organic performance validated the strategic path though FX and execution noise reminded investors of short‑term headline risk. The overall view remained that of a long‑term compounder with diversified secular exposures.

The stock rallied on deal and earnings proof points with brief sharp selloffs around quarterly and FX misses, posting overall higher highs through 2025.

Q4 2025 and early 2026 — Mixed quarter, cautious outlook revised upward

Q4 2025 results published on March 5, 2026 delivered full‑year 2025 guidance but a Q4 miss and cautious initial 2026 outlook triggered an immediate selloff. Management proposed an unchanged dividend of €2.20 per share. In August 2026 Merck raised 2026 adjusted EBITDA guidance to €5.9–6.3bn after stronger‑than‑expected semiconductor and life‑science demand [4][12][15].

The March selloff temporarily reclassified the stock from steady compounder to swing‑trade on execution and FX. The August guidance raise restored confidence that Electronics and Life Science end markets remain robust, shifting perception back to resilient secular growth with cyclical boosts from semiconductor demand.

The stock experienced a sharp drawdown on the March Q4 miss and cautious outlook, followed by a recovery rally into August as guidance was raised. Overall the stock remains in a multi‑year uptrend though with higher short‑term volatility.

At the current price of 140, the stock sits inside the recovery rally post‑August 2026 guidance raise, consistent with renewed uptrend and improved momentum after the spring drawdown.